This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, L. Articles by Lloyd, R. V. Search for Related Content PubMed PubMed Citation Articles by Jin, L. Articles by Lloyd, R. V.

Prolactin Receptor Messenger Ribonucleic Acid in Normal and Neoplastic Human Pituitary Tissues¹

Department of Laboratory Medicine and Pathology (L.J., X.Q., E.K., B.W.S., R.C.-R., R.V.L.), Division of Endocrinology/Metabolism and Internal Medicine (C.A.), and the Department of Neurologic Surgery (D.H.D.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905; and the Department of Pathology, St. Michaels Hospital (K.K.), Toronto, Canada

Address all correspondence and requests for reprints to: R. V. Lloyd, M.D., Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905.

We examined the specific cell types in normal human pituitaries that expressed PRL receptor (PRL-R) messenger ribonucleic acid (mRNA) by combined in situ hybridization and immunohistochemistry. The distribution of PRL-R mRNA in 28 pituitary adenomas was examined by in situ hybridization and reverse transcription-PCR in 12 cases of adenomas. In another set of experiments, 34 PRL adenomas from men, women, and bromocriptine-treated patients were analyzed for PRL-R by in situ hybridization.

In the normal pituitary, PRL- and LH-producing cells had significantly more mean grain counts per cell and higher percentages of cells positive for PRL-R than GH and TSH cells. PRL-R mRNA was present in all groups of adenomas by in situ hybridization and reverse transcription-PCR. PRL adenomas had a significantly higher density of labeling compared to other adenoma types. Although there was no difference in the levels of PRL-R mRNA in PRL adenomas from men and premenopausal and postmenopausal women, patients treated with bromocriptine before pituitary surgery had significantly lower levels of PRL-R compared to all other groups. These results indicate that in the normal pituitary, PRL and LH cells have the highest level of PRL-R mRNA, whereas PRL adenomas have significantly higher levels of PRL-R mRNA than other types of adenomas, and bromocriptine treatment decreases the levels of PRL-R mRNA in PRL adenomas.

This article has been cited by other articles:

				D. R. Grattan, C. L. Jasoni, X. Liu, G. M. Anderson, and A. E. Herbison Prolactin Regulation of Gonadotropin-Releasing Hormone Neurons to Suppress Luteinizing Hormone Secretion in Mice Endocrinology, September 1, 2007; 148(9): 4344 - 4351. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]

				L. J. S. Brokken, W. M. Wiersinga, and M. F. Prummel Thyrotropin Receptor Autoantibodies Are Associated with Continued Thyrotropin Suppression in Treated Euthyroid Graves' Disease Patients J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4135 - 4138. [Abstract] [Full Text] [PDF]

				D. J. Tortonese, J. Brooks, P. M. Ingleton, and A. S. McNeilly Detection of Prolactin Receptor Gene Expression in the Sheep Pituitary Gland and Visualization of the Specific Translation of the Signal in Gonadotrophs Endocrinology, December 1, 1998; 139(12): 5215 - 5223. [Abstract] [Full Text] [PDF]

				F. de Zegher, B. Spitz, G. Van den Berghe, D. Lemmens, K. Vanweser, K. Keppens, and C. Y. Bowers Postpartum Hyperprolactinemia and Hyporesponsiveness of Growth Hormone (GH) to GH-Releasing Peptide J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 103 - 106. [Abstract] [Full Text]